Drugs / BI 771716
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06006585 | Oct 2023 → May 2024 | diffuse secondary choroid atrophy | Boehringer Ingelheim | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06722157 | Jan 2025 → Oct 2026 expected | age-related macular degeneration | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-05 | CDR-Life AG | Results Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results cdr-life.com ↗
BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-05 | CDR-Life AG | Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results cdr-life.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 771716 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06722157 ↗ |
| Route | Intravitreal | “Intravitreal Single Rising Doses” NCT06006585 ↗ |